Michael F Joyce

US Patent:

20200273189, Aug 27, 2020

Filed:

Feb 22, 2019

Appl. No.:

16/283139

Inventors:

- McLean VA, US
Andrea Blackwell - White Plains MD, US
Jo Clark - Camarillo CA, US
Erin Bradford - Arlington VA, US
Nathan Schwan - Jamaica Plain MA, US
Saba Ali - Gaithersburg MD, US
Michael Joyce - Falls Church VA, US
Nat Burgwyn - Washington DC, US
Kevin Chiu - Gaithersburg MD, US
Carver Sorensen - Arlington VA, US
Michael Tong - Arlington VA, US

Assignee:

Booz Allen Hamilton Inc. - McLean VA

International Classification:

G06T 7/564
G06K 9/00
G06T 7/00

Abstract:

A computer-implemented method for assessing an image sentiment. The method can include receiving an image to identify a region of interest in the image; determining an image sentiment value associated with the image based on the region of interest, or a classification of the image; and displaying an indication of the image sentiment value with a spatial (e.g. geographical) location.

US Patent:

20200230229, Jul 23, 2020

Filed:

Oct 3, 2017

Appl. No.:

16/338964

Inventors:

- Bethesda, MD, US
Rui Kong - Bethesda MD, US
Tongqing Zhou - Boyds MD, US
John Mascola - Rockville MD, US
Kai Xu - Bethesda MD, US
Michael Gordon Joyce - Washington DC, US
Cheng Cheng - Bethesda MD, US
Kevin Liu - Bethesda MD, US
Baoshan Zhang - Bethesda MD, US
Li Ou - Potomac MD, US
Wing-Pui Kong - Germantown MD, US
Yongping Yang - Potomac MD, US

Assignee:

THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVIC - Bethesda, MD

International Classification:

A61K 39/21
C12N 7/00
A61K 47/64
A61P 31/18
C07K 14/005

Abstract:

Embodiments of immunogens based on the HIV-1 Env fusion peptide and methods of their use and production are disclosed. Nucleic acid molecules encoding the immunogens are also provided. In several embodiments, the immunogens can be used to generate an immune response to HIV-1 Env in a subject, for example, to treat or prevent an HIV-1 infection in the subject.

US Patent:

20200190168, Jun 18, 2020

Filed:

Apr 25, 2018

Appl. No.:

16/608386

Inventors:

- Bethesda MD, US
Michael Gordon JOYCE - Washington DC, US
Jeffrey I. COHEN - Silver Spring MD, US

International Classification:

C07K 16/08
C07K 14/05

Abstract:

Antibodies and compositions of matter useful for the detection, diagnosis and treatment of Epstein Barr Virus infection in mammals, and to methods of using those compositions of matter for the same. Also disclosed are proteins, referred to as anti-gp350 antibody probes, and anti-gp350 B-cell probes, that maintain the epitope structure of the CR2-binding region of gp350, but do not bind CR2.

US Patent:

20190256579, Aug 22, 2019

Filed:

May 3, 2019

Appl. No.:

16/403211

Inventors:

- Bethesda MD, US
Wing-Pui Kong - Germantown MD, US
Kayvon Modjarrad - Bethesda MD, US
Lingshu Wang - North Potomac MD, US
Wei Shi - Rockville MD, US
Michael Gordon Joyce - Washington DC, US
Masaru Kanekiyo - Chevy Chase MD, US
John Mascola - Rockville MD, US

Assignee:

The U.S.A., as represented by the Secretary, Department of Health and Human Services - Bethesda MD

International Classification:

C07K 16/10
C07K 14/005
C07K 14/165
A61K 39/215
G01N 33/569
A61K 39/12

Abstract:

Methods of inducing an immune response in a subject to the Middle East respiratory syndrome coronavirus (MERS-CoV) are provided. In several embodiments, the immune response is a protective immune response that inhibits or prevents MERS-CoV infection in the subject. Recombinant MERS-CoV polypeptides and nucleic acid molecules encoding same are also provided. Additionally, neutralizing antibodies that specifically bind to MERS-CoV S protein and antigen binding fragments thereof are disclosed. The antibodies and antigen binding fragments are useful, for example, in methods of detecting MERS-CoV S protein in a sample or in a subject, as well as methods of preventing and treating a MERS-CoV infection in a subject.

US Patent:

20190112340, Apr 18, 2019

Filed:

Mar 29, 2017

Appl. No.:

16/089993

Inventors:

- Bethesda MD, US
Barney Graham - Rockville MD, US
John Mascola - Rockville MD, US
Li Ou - Potomac MD, US
Aliaksandr Druz - Germantown MD, US
Man Chen - Bethesda MD, US
Wing-Pui Kong - Germantown MD, US
Ivelin Stefanov Georgiev - Nashville TN, US
Emily Rundlet - New York NY, US
Michael Gordon Joyce - Washington DC, US
Yaroslav Tsybovsky - Frederick MD, US
Paul Thomas - Washington DC, US
Marie Pancera - Seattle WA, US
Mallika Sastry - Rockville MD, US
Cinque Soto - Nashville TN, US
Joseph Van Galen - North Wales PA, US
Guillaume Stewart-Jones - Bethesda MD, US
Yongping Yang - Potomac MD, US
Baoshan Zhang - Bethesda MD, US
Ulrich Baxa - Frederick MD, US

Assignee:

The United States of America, as represented by the Secretary, Department of Health and Human - Bethesda MD

International Classification:

C07K 14/005
A61P 31/14
A61P 37/04

Abstract:

Embodiments of a recombinant Respiratory Syncytial Virus (RSV) F ectodomain trimer stabilized in a prefusion conformation are provided. Also disclosed are nucleic acids encoding the RSV F ectodomain trimer and methods of producing the RSV F ectodomain trimer. Methods for inducing an immune response in a subject are also disclosed. In some embodiments, the method can be a method for treating or preventing a RSV infection in a subject by administering a therapeutically effective amount of the recombinant RSV F ectodomain trimer to the subject.

US Patent:

20180319846, Nov 8, 2018

Filed:

Jul 2, 2018

Appl. No.:

16/025858

Inventors:

- Bethesda MD, US
Barney S. Graham - Rockville MD, US
Jason S. McLellan - Austin TX, US
Jeffrey Boyington - Clarksburg MD, US
Lei Chen - Rockville MD, US
Man Chen - Bethesda MD, US
Ivelin Stefanov Georgiev - Nashville TN, US
Jason Gorman - Washington DC, US
Michael Gordon Joyce - Washington DC, US
Masaru Kanekiyo - Chevy Chase MD, US
Gilad Ofek - Gaithersburg MD, US
Marie Pancera - Seattle WA, US
Mallika Sastry - Rockville MD, US
Cinque Soto - Rockville MD, US
Sanjay Srivatsan - Lilburn GA, US
Guillaume Stewart-Jones - Bethesda MD, US
Yongping Yang - Potomac MD, US
Baoshan Zhang - Bethesda MD, US
Tongqing Zhou - Boyds MD, US

Assignee:

The United States of America,as represented by the Secretary,Department of Helath and Human Services - Bethesda MD

International Classification:

C07K 14/005
A61K 39/155
C12N 7/00
A61K 39/12
G01N 33/564
A61K 39/00

Abstract:

Disclosed are Respiratory Syncytial Virus (RSV) antigens including a recombinant RSV F protein stabilized in a prefusion conformation. Also disclosed are nucleic acids encoding the antigens and methods of producing the antigens. Methods for generating an immune response in a subject are also disclosed. In some embodiments, the method is a method for treating or preventing a RSV infection in a subject by administering a therapeutically effective amount of the antigen to the subject.

US Patent:

20180244756, Aug 30, 2018

Filed:

Feb 24, 2016

Appl. No.:

15/553466

Inventors:

- Bethesda MD, US
Wing-Pui Kong - Germantown MD, US
Kayvon Modjarrad - Bethesda MD, US
Lingshu Wang - North Potomac MD, US
Wei Shi - Rockville MD, US
Michael Gordon Joyce - Washington DC, US
Masaru Kanekiyo - Chevy Chase MD, US
John Mascola - Rockville MD, US

Assignee:

The United States of America, as Represented by the Secretary, Dept. of Health and Human Services - Bethesda MD

International Classification:

C07K 16/10
A61K 39/215
C07K 14/005
G01N 33/569

Abstract:

Methods of inducing an immune response in a subject to the Middle East respiratory syndrome coronavirus (MERS-CoV) are provided. In several embodiments, the immune response is a protective immune response that inhibits or prevents MERS-CoV infection in the subject. Recombinant MERS-CoV polypeptides and nucleic acid molecules encoding same are also provided. Additionally, neutralizing antibodies that specifically bind to MERS-CoV S protein and antigen binding fragments thereof are disclosed. The antibodies and antigen binding fragments are useful, for example, in methods of detecting MERS-CoV S protein in a sample or in a subject, as well as methods of preventing and treating a MERS-CoV infection in a subject.

US Patent:

20160046675, Feb 18, 2016

Filed:

Mar 13, 2014

Appl. No.:

14/776651

Inventors:

- Bethesda MD, US
Barney S. Graham - Rockville MD, US
Jason S. McLellan - Norwich VT, US
Jeffrey Boyington - Clarksburg MD, US
Lei Chen - Rockville MD, US
Man Chen - Bethesda MD, US
Ivelin Stefanov Georgiev - Gaithersburg MD, US
Jason Gorman - Washington DC, US
Michael Gordon Joyce - Washington DC, US
Masaru Kanekiyo - Chevy Chase MD, US
Gilad Ofek - Gaithersburg MD, US
Marie Pancera - McLean VA, US
Mallika Sastry - Rockville MD, US
Cinque Soto - Rockville MD, US
Sanjay Srivatsan - Lilburn GA, US
Guillaume Stewart-Jones - Bethesda MD, US
Yongping Yang - Potomac MD, US
Baoshan Zhang - Bethesda MD, US
Tongqing Zhou - Boyds MD, US

Assignee:

The USA, as represented by the Secretary, Departm- ent of Health and Human Service - Bethesda MD

International Classification:

C07K 14/005
A61K 39/155
G01N 33/564
C12N 7/00

Abstract:

Disclosed are Respiratory Syncytial Virus (RSV) antigens including a recombinant RSV F protein stabilized in a prefusion conformation. Also disclosed are nucleic acids encoding the antigens and methods of producing the antigens. Methods for generating an immune response in a subject are also disclosed. In some embodiments, the method is a method for treating or preventing a RSV infection in a subject by administering a therapeutically effective amount of the antigen to the subject.